FDA — authorised 12 May 1976
- Application: NDA017573
- Marketing authorisation holder: SCHERING
- Local brand name: VANCERIL
- Indication: AEROSOL, METERED — INHALATION
- Status: approved
🇺🇸 BECLOMETHASONE DIPROPIONATE in United States
FDA authorised BECLOMETHASONE DIPROPIONATE on 12 May 1976 · 3,390 US adverse-event reports
Marketing authorisations
FDA — authorised 15 September 2000
- Application: NDA020911
- Marketing authorisation holder: TEVA BRANDED PHARM
- Local brand name: QVAR 40
- Indication: AEROSOL, METERED — INHALATION
- Status: approved
FDA — authorised 16 December 2025
- Application: ANDA213811
- Marketing authorisation holder: AMNEAL IRELAND LTD
- Status: approved
FDA
- Status: approved
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 3,390
Most-reported reactions
- Dyspnoea — 588 reports (17.35%)
- Asthma — 358 reports (10.56%)
- Diarrhoea — 358 reports (10.56%)
- Vomiting — 330 reports (9.73%)
- Nausea — 326 reports (9.62%)
- Pneumonia — 306 reports (9.03%)
- Fatigue — 302 reports (8.91%)
- Malaise — 297 reports (8.76%)
- Headache — 277 reports (8.17%)
- Dizziness — 248 reports (7.32%)
BECLOMETHASONE DIPROPIONATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is BECLOMETHASONE DIPROPIONATE approved in United States?
Yes. FDA authorised it on 12 May 1976; FDA authorised it on 15 September 2000; FDA authorised it on 16 December 2025.
Who is the marketing authorisation holder for BECLOMETHASONE DIPROPIONATE in United States?
SCHERING holds the US marketing authorisation.